It is demonstrated that AAV2-AQP1 expression enhances fluid secretion in human LSGs and highlight fibrosis-associated loss of glandular parenchyma as a major barrier to therapeutic efficacy.
Abstract
INTRODUCTION
Sjögren's disease (SjD) is a systemic autoimmune disease characterized by dry mouth, dry eyes, and profound fatigue. Preclinical studies suggest that AQP1 gene expression in salivary glands corrects salivary hypofunction in preclinical and clinical studies of radiation-induced xerostomia and improves salivary and lacrimal function in SjD mouse models.
SUBJECTS AND
Methods
To evaluate its therapeutic potential, we tested AQP1 gene therapy using labial salivary gland (LSG) biopsies from patients with SjD, non-SjD, and healthy volunteer glands (HV).
Results
Ex vivo cultures of LSG lobules were viable, responsive to stimulation, and transducible with an AAV2 vector encoding AQP1. AQP1 expression increased fluid secretion in most samples, with recovery reaching up to 80% of healthy volunteer levels. Baseline transcriptomic analysis identifies 94 genes that correlated with treatment response, with inflammatory and epithelial signature correlating with success and fibrotic signatures with non-response. Histological evaluation confirmed greater fibrosis in non-responding samples. Thus, treatment effects were functionally significant but transcriptionally minimal indicating targeted therapeutic action without altering homeostatic transcription.
Conclusion
These findings demonstrate that AAV2-AQP1 expression enhances fluid secretion in human LSGs and highlight fibrosis-associated loss of glandular parenchyma as a major barrier to therapeutic efficacy.
OBJECTIVE
Salivary flow may follow a circadian rhythm regulated by clock genes and aquaporins. Because aquaporin 5 dysregulation may contribute to Sjögren's disease, we investigated whether daily unstimulated and stimulated salivary flow patterns differed between participants with Sjögren's disease and healthy controls...
Mouna Alsunni, Matthew D. Finkelman, Mabi L. Singh et al.· Oral Diseases· 0 citations
Exogenous relaxin shows therapeutic potential for DED in SS, demonstrated by clinical improvements and reduced inflammatory markers in an animal model of SS.
Lucimeire N. Carvalho, T. Wakamatsu, C. Gil et al.· Experimental Eye Research· 0 citations
OBJECTIVE
Chronic recurrent multifocal osteomyelitis (CRMO) is a pediatric autoinflammatory bone disease with poorly defined pathophysiology and limited biomarkers. Murine models implicate neutrophils, neutrophil-derived IL-1β, and the adaptor protein PSTPIP2, but direct evidence in human CRMO is lacking. This study ai...
N. Pavliuchenko, P. Daněk, Hana Malcová et al.· Arthritis & Rheumatology· 0 citations
BACKGROUND
Mepolizumab, an anti-IL5 monoclonal antibody, effectively reduces exacerbations and improves disease control in severe eosinophilic asthma (SEA). While this treatment rapidly decreases blood eosinophil counts, some patients continue to experience asthma symptoms, suggesting that other features beyond eosinop...
P. Miguéns-Suárez, Sara Vázquez-Mera, L. Martelo-Vidal et al.· Allergy. European Journal of...· 0 citations
Juvenile dermatomyositis (JDM) is a rare autoimmune disease in which children develop inflammation of the muscles and skin. This can lead to severe muscle weakness and difficulties with walking, swallowing, or even breathing. Unfortunately, current treatments are not effective enough for around half of children with JD...
Saskia R. Veldkamp· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.